193 related articles for article (PubMed ID: 11953478)
1. Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
Wasmuth JC; Herhaus C; Römer K; Salzberger B; Kaiser R; Schliefer K; Voigt E; Rockstroh JK
AIDS; 2002 May; 16(7):1077-8. PubMed ID: 11953478
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
de Truchis P; Force G; Welker Y; Mechali D; Pulik M; Chemlal K; Rouveix E; Devidas A; Praindhui D; Mamet JP;
J Acquir Immune Defic Syndr; 2002 Oct; 31(2):178-82. PubMed ID: 12394796
[TBL] [Abstract][Full Text] [Related]
3. What's new and what's next.
Fakuda D
Posit Dir News; 1998 Jan; 10(1):25-9. PubMed ID: 11365053
[TBL] [Abstract][Full Text] [Related]
4. Dupont pharmaceuticals study 006 for Sustiva.
Bartlett JG
Hopkins HIV Rep; 1998 Sep; 10(5):1. PubMed ID: 11365772
[TBL] [Abstract][Full Text] [Related]
5. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
[TBL] [Abstract][Full Text] [Related]
6. Switching from protease inhibitors to the non-nuke efavirenz.
TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
[No Abstract] [Full Text] [Related]
7. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.
Moyle GJ; Wilkins E; Leen C; Cheesbrough A; Reynolds B; Gazzard BG
AIDS; 2000 Jul; 14(10):1453-4. PubMed ID: 10930162
[No Abstract] [Full Text] [Related]
8. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
9. Four new antiretroviral medications will soon offer more options to HIV patients.
Murphy MJ
Fac Notes (New Orleans La); 1998; 10(4):1-3. PubMed ID: 11365545
[TBL] [Abstract][Full Text] [Related]
10. New expanded access drugs for use in combination therapy.
Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
[TBL] [Abstract][Full Text] [Related]
11. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
12. Options when HIV treatments fail.
Treat Rev; 1998; (No 28):7-9. PubMed ID: 11365426
[TBL] [Abstract][Full Text] [Related]
13. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
[TBL] [Abstract][Full Text] [Related]
14. [HIV infections: mortality reduced only in developed countries].
Wehr A
Dtsch Med Wochenschr; 1999 May; 124(18):A8-9. PubMed ID: 10356577
[No Abstract] [Full Text] [Related]
15. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
16. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
Moyle GJ; Gazzard BG
AIDS; 2002 May; 16(7):1086-7. PubMed ID: 11953482
[No Abstract] [Full Text] [Related]
17. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
[TBL] [Abstract][Full Text] [Related]
18. Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
Feinberg J
AIDS Clin Care; 2006 Nov; 18(11):99. PubMed ID: 17183745
[No Abstract] [Full Text] [Related]
19. Antiretroviral rounds. When success is a pain.
Bartlett JG; del Rio C
AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
[No Abstract] [Full Text] [Related]
20. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
